title: Advances in the clinical management of inhibitors in hemophilia A and B.
abstract: Inhibitors to factor (F)VIII or FIX are the most serious and challenging complication of hemophilia treatment, increasing morbidity and mortality because bleeds no longer respond to standard clotting factor replacement therapy. For patients with high-titer inhibitors, immune tolerance induction achieved through regular factor exposure is the only proven therapy capable of Inhibitor eradication and is almost always indicated for inhibitors of recent onset. Bypassing therapy is used to treat and prevent bleeding, but neither of the two currently available bypassing agents has the predictable hemostatic efficacy of factor replacement in hemophilia patients without inhibitors. Major research efforts are focused on the development of new, more potent therapies for the management of patients with inhibitors.
authors.affiliation: Departments of Medicine, Pediatrics, and Pathology, Tulane University School of Medicine, New Orleans, LA, USA. Electronic address: cleissi@tulane.edu.
authors.forename: Cindy A
authors.initials: CA
authors.lastname: Leissinger
mesh_terms: D000208:Acute Disease; D000818:Animals; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D002836:Hemophilia B / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000209:etiology; D006487:Hemostasis; D006801:Humans; D007108:Immune Tolerance
keywords: Acute bleeding; Bypassing therapy; Hemophilia; Immune tolerance induction; Inhibitors; Prophylaxis